The highs and lows of serous ovarian cancer Review
| Authors: | Grisham, R. N.; Manning-Geist, B. L.; Chui, M. H. |
| Review Title: | The highs and lows of serous ovarian cancer |
| Abstract: | Low-grade serous ovarian cancer was initially described as a distinct type of rare epithelial ovarian cancer 20 years ago; however, only recently have physicians begun to leverage the understanding of the clinical behavior and molecular profile of this disease for treatment. The use of routine next-generation sequencing has allowed a deeper understanding of the molecular drivers of this disease and shown how molecular alterations in mitogen-activated protein kinase pathway genes such as KRAS and BRAF can affect overall prognosis and disease behavior. The use of targeted therapies, including MEK inhibitors, BRAF kinase inhibitors, and other investigational targeted therapies are changing the way this disease is viewed and treated. In addition, endocrine therapy can provide prolonged disease stability with generally mild toxicity, as well as promising response rates in recent studies examining combination therapy with CDK 4/6 inhibitors in the upfront and recurrent setting. Once seen merely as a chemo-resistant form of ovarian cancer, recent studies have worked to harness the unique features of low-grade serous ovarian cancer to provide individualized treatment options for patients with this disease. © 2023 American Cancer Society. |
| Keywords: | genetics; mutation; cancer grading; ovarian cancer; ovarian neoplasms; metabolism; ovary tumor; ovary carcinoma; cystadenocarcinoma, serous; b raf kinase; mapk; mek; proto-oncogene proteins b-raf; cystadenocarcinoma; low-grade serous; neoplasm grading; humans; prognosis; human; female; rare tumors; carcinoma, ovarian epithelial |
| Journal Title: | Cancer |
| Volume: | 129 |
| Issue: | 17 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-09-01 |
| Start Page: | 2613 |
| End Page: | 2620 |
| Language: | English |
| DOI: | 10.1002/cncr.34903 |
| PUBMED: | 37366225 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Rachel N. Grisham -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work